# Junta clínica — PT-pseudo_d49b896a09e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d49b896a09e6",
  "pid": "PT-pseudo_d49b896a09e6",
  "task": 1,
  "psa": 6.7,
  "age": 67,
  "months": 1,
  "pirads": "4",
  "psad": 0.2,
  "psav": 1.78,
  "psap": 4.4,
  "vol": 36.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7934635,
  "medhx": "Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)",
  "meds": "rosuvastatin, aspirin 80 mg, atorvastatin",
  "notes": "PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Coronary artery disease",
    "Obesity (BMI >30)"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "178 cm",
    "bmi": "29.4",
    "bp": "146/77 mmHg",
    "hr": "77 bpm",
    "smoking": "Current smoker (17 pack-yr)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "An upward PSA trend alongside a previously positive biopsy necessitates urological review."
    },
    {
      "s": "History",
      "t": "A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly."
    }
  ],
  "occupation": "retired warehouse worker",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Ophthalmology — cataract review"
  ],
  "alcohol": "19 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "UMCG (Groningen)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d49b896a09e6
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.2 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 4.4 ng/mL
  - Prostate volume: 36.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7934635 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Current medication: rosuvastatin, aspirin 80 mg, atorvastatin
  - Allergies: NKA
  - Additional notes: PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.

Vitals: weight 93 kg, height 178 cm, BMI 29.4, BP 146/77 mmHg, HR 77 bpm. Smoking: Current smoker (17 pack-yr).

Chief complaint: An upward PSA trend alongside a previously positive biopsy necessitates urological review.

History: A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable.

Physical examination: DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly.

Patient info: retired warehouse worker; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 19 units / week; exercise Running 3x/week, 5 km; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.74
  uncertainty  +/- 0.12 epistemic (95% band 0.51-0.98); among patients I cannot tell apart the outcome was 0.82 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 3 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 67 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 6.7 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 36 mL (1% of my signal; from log_vol, vol) · PSA density = 0.2 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.79 (1% of my signal; from cspca) · PI-RADS = 4 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 67 · DRE = Normal · PSA = 6.7 ng/mL · prostate volume = 36 mL · PSA density = 0.2 · PI-RADS = 4 · comorbidity = 3 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 48 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 0.72: PI-RADS 4, PSA 6.8, PSAD 0.2, age 62, DRE Normal -> DEFER (borderline). He wrote: "All depends if the lesion has grown in size since 2024. If stable no biopsy , if increased in size I will do a biopsy."
  2. distance 0.79: PI-RADS 4, PSA 5.2, PSAD 0.151, age 68, DRE Normal -> BIOPSY (uncertain). He wrote: "Again missing earlier ISUP grading and if the PIRADS 4 lesion is stabile or growing"
  3. distance 0.93: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."

PRECEDENT: DEFER (weighted vote 0.34 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · PI-RADS = 4
  noted      family history = not opened (0 of 91) · age = 67 · DRE = Normal · PSA = 6.7 ng/mL · prostate volume = 36 mL · PSA density = 0.2 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 67 · PSA = 6.7 ng/mL · PI-RADS = 4
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 36 mL · PSA density = 0.2 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guidelines discuss using PI-RADS scores and PSA density to guide biopsy decisions. "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy." This requires assessing the patient's PI-RADS score and PSA density against established risk-adapted matrices.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline makes the variable PSA density decisive when combined with the PI-RADS score. The guideline suggests using the PSA-D cut-off of 0.15ng/mL/cc to guide the decision. The guideline requires the patient's PI-RADS score and PSA density to be assessed against this matrix. The guideline needs the prior grade of the biopsy to determine the appropriate management pathway.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive the guideline suggests the decision depends on the documented grade of the prior biopsy.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: at 1.78 ng/mL/yr the guideline suggests this should be considered in the risk-adapted matrix.
laboratory_results - the PSA density: at 0.2 ng/mL² the guideline suggests this value is used in the risk-adapted matrix.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on the documented grade of the prior biopsy and how the current imaging and lab results fit the EAU risk-adapted matrix.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension differ from the earlier study?
  psa_trend (get_psa_trend) -> How should the PSA velocity of 1.78 ng/mL/yr be considered in the risk-adapted matrix?
  previous_notes (get_previous_notes) -> What is the documented grade (Gleason/ISUP) of the prior biopsy and is a surveillance protocol in place?
  laboratory_results (get_lab_results) -> How is the PSA density of 0.2 ng/mL² used in the risk-adapted matrix?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?
  Q2. Does the radiology_report indicate if the lesion has changed in size since the earlier study?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report: UMCG Groningen | 28 January 2025 | mpMRI prostate. The lesion size or extraprostatic extension differ from the earlier study? The report states: "There is no seminal vesicle invasion or extraprostatic extension."
psa_trend: How should the PSA velocity of 1.78 ng/mL/yr be considered in the risk-adapted matrix? The PSA velocity of 1.78 ng/mL/yr should be considered in the risk-adapted matrix.
previous_notes: What is the documented grade (Gleason/ISUP) of the prior biopsy and is a surveillance protocol in place? The documented grade of the prior biopsy is not explicitly stated in the retrieved notes, and the notes mention he was referred for further assessment after a positive biopsy.
laboratory_results: How is the PSA density of 0.2 ng/mL² used in the risk-adapted matrix? The PSA density of 0.2 ng/mL² is used in the risk-adapted matrix.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes did not contain specific family history information.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- The PI-RADS score of 4 and PSA density of 0.2 ng/mL² are both factors used in the EAU risk-adapted matrix.
- The PSA velocity of 1.78 ng/mL/yr suggests a need for consideration within that matrix.
AGAINST sampling this patient now:
- The prior biopsy status is positive, and the documented grade is not explicitly known from the retrieved notes.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.70 ng/mL over 4 points spanning 15 months; velocity +2.95 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 8.9 ng/mL, conformal 95% band 2.6-31.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 6.7 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.78
  uncertainty  +/- 0.11 epistemic (95% band 0.56-1.00), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 4 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Normal (5% of my signal; from dre_suspicious) · PSA = 6.7 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 36 mL (4% of my signal; from log_vol, vol) · PSA density = 0.2 (0% of my signal; from psad_calc) · comorbidity = 3 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.74  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.78  ('firm' tier, fusion_full; weight 4.5)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.34  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.76 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('firm' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-EXPERIENCE. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          67                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psa          6.7 ng/mL                    E1:not E3:not cohort:not library:not E2:not          -> important
  vol          36 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.2                          E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.79                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       4                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  3 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes, laboratory_results) address the moderator's questions. The `previous_notes` state the documented grade of the prior biopsy is not explicitly stated, and the `radiology_report` confirms no change in lesion size or extraprostatic extension.

ALIGNMENT WITH THE PANEL
The retrieved evidence is inconclusive regarding the prior biopsy grade, which the PANEL-PROTOCOL noted as "none recorded." However, the evidence aligns with the PANEL's decision to proceed with BIOPSY, as the weighted vote of the experts resulted in BIOPSY, despite the missing prior grade.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? This question remains unanswered, as the `previous_notes` state the grade is not explicitly stated.
Q2. Does the radiology_report indicate if the lesion has changed in size since the earlier study? The `radiology_report` indicates no change in size or extraprostatic extension.

WHAT CARRIES WEIGHT, AND WHY
prior biopsy: Positive (noted) because the panel weighted this as important, but the specific grade is missing. age: 67 (important) as per the panel, which is noted. psa: 6.7 ng/mL (important) as per the panel, which is noted. pirads: 4 (important) as per the panel, which is noted. I would move the weight on prior biopsy from 'noted' to 'important' because the lack of grade is a critical missing piece for the EAU matrix. My confidence in the record as it stands is borderline due to the missing prior grade.

MY SUGGESTION TO THE CHAIR
Given the panel's weighted decision of BIOPSY, and the fact that the key missing piece (prior grade) is not explicitly documented, I suggest proceeding with the biopsy as per the panel's consensus, but with explicit documentation of the uncertainty regarding the prior grade.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

67y male, PSA 6.7, PI-RADS 4, PSAD 0.2. Prior biopsy grade is not recorded, making sampling necessary for management planning. The rising PSA velocity of 1.78 ng/mL/yr and unrecorded prior grade pull towards further tissue sampling. Biopsy recommended to establish baseline pathology.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
